| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | gCSI | pan-cancer | AAC | -0.12 | 0.02 |
| mRNA | UNC0638 | GDSC1000 | pan-cancer | AAC | 0.065 | 0.03 |
| mRNA | Irinotecan | FIMM | pan-cancer | AAC | -0.25 | 0.03 |
| mRNA | HG-5-113-01 | GDSC1000 | pan-cancer | AAC | 0.098 | 0.03 |
| mRNA | MG-132 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.03 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.071 | 0.03 |
| mRNA | selumetinib:PLX-4032 (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.075 | 0.03 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.072 | 0.03 |
| mRNA | BRD-K70511574 | CTRPv2 | pan-cancer | AAC | 0.068 | 0.03 |
| mRNA | SR-II-138A | CTRPv2 | pan-cancer | AAC | 0.066 | 0.03 |